Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America
By a News Reporter-Staff News Editor at Physician Law Weekly -- Fresh data on Marijuana/Cannabis - Marijuana Usage are presented in a new report. According to news reporting from Beer Sheva, Israel, by NewsRx journalists, research stated, “In 1937, the United States of America criminalized the use of cannabis and as a result its use decreased rapidly. In recent decades, there is a growing interest in the wide range of medical uses of cannabis and its constituents; however, the laws and regulations are substantially different between countries.”
The news correspondents obtained a quote from the research from the Ben-Gurion University of the Negev, “Laws differentiate between raw herbal cannabis, cannabis extracts, and cannabinoid-based medicines. Both the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) do not approve the use of herbal cannabis or its extracts. The FDA approved several cannabinoid-based medicines, so did 23 European countries and Canada. However, only four of the reviewed countries have fully authorized the medical use of herbal cannabis-Canada, Germany, Israel and the Netherlands, together with more than 50% of the states in the United States. Most of the regulators allow the physicians to decide what specific indications they will prescribe cannabis for, but some regulators dictate only specific indications.”
According to the news reporters, the research concluded: “The aim of this article is to review the current (as of November 2017) regulations of medical cannabis use in Europe and North America.”
For more information on this research see: Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America. European Journal of Internal Medicine , 2018;49():2-6. European Journal of Internal Medicine can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Internal Medicine - http://www.journals.elsevier.com/european-journal-of-internal-medicine/)
Our news journalists report that additional information may be obtained by contacting R. Abuhasira, Ben Gurion University of the Negev, Fac Hlth Sci, Beer Sheva, Israel. Additional authors for this research include L. Shbiro and Y. Landschaft.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.ejim.2018.01.001. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
CITATION: (2018-04-11), Findings on Marijuana Usage Reported by Investigators at Ben-Gurion University of the Negev (Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America), Physician Law Weekly, 51, ISSN: 1551-5303, BUTTER® ID: 015443857
From the newsletter Physician Law Weekly.
https://www.newsrx.com/Butter/#!Search:a=15443857
This is a NewsRx® article created by NewsRx® and posted by NewsRx®. As proof that we are NewsRx® posting NewsRx® content, we have added a link to this steemit page on our main corporate website. The link is at the bottom left under "site links" at https://www.newsrx.com/NewsRxCorp/.
We have been in business for more than 20 years and our full contact information is available on our main corporate website.
We only upvote our posts after at least one other user has upvoted the article to increase the curation awards of upvoters.
NewsRx® offers 195 weekly newsletters providing comprehensive information on all professional topics, ranging from health, pharma and life science to business, tech, energy, law, and finance. Our newsletters report only the most relevant and authoritative information from qualified sources.